Alaunos Therapeutics (TCRT) Cash from Investing Activities (2009 - 2025)
Alaunos Therapeutics' (TCRT) quarterly Cash from Investing Activities came in at -$1000.0 in Q4 2025, down 100.07% on a QoQ basis from $1.5 million in Q4 2023.
Alaunos Therapeutics (TCRT) Cash from Investing Activities (2009 - 2025) Analysis & Trends
Alaunos Therapeutics (TCRT) has 16 years of Cash from Investing Activities data on file, last reported at -$1000.0 in Q4 2025.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1000.0 (changed N/A YoY) and the FY2025 annual result came in at -$98000.0, changed N/A from the prior year.
- Cash from Investing Activities slipped to -$1000.0 in Q4 2025, from $1.5 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $1.5 million in Q4 2023 to a low of -$1.9 million in Q2 2021.
- A 4-year average of -$167000.0 and a median of -$57000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 1716.13% in 2023, down 136.84% in 2023.
- Tracing TCRT's Cash from Investing Activities over 4 years: stood at -$359000.0 in 2021, then soared by 74.09% to -$93000.0 in 2022, then surged by 1716.13% to $1.5 million in 2023, then slumped by 100.07% to -$1000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$1000.0 (Q4 2025), $1.5 million (Q4 2023), and $1000.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2023 | 1.50 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | -135,000.00 |
| Jun 30, 2023 | -135,000.00 |
| Mar 31, 2023 | -23,000.00 |
| Mar 31, 2023 | -23,000.00 |
| Dec 31, 2022 | -93,000.00 |
| Dec 31, 2022 | -93,000.00 |
| Sep 30, 2022 | -14,000.00 |
| Sep 30, 2022 | -14,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Mar 31, 2022 | -29,000.00 |
| Mar 31, 2022 | -29,000.00 |
| Dec 31, 2021 | -359,000.00 |
| Dec 31, 2021 | -359,000.00 |